16.60

2.28% 0.37

After Hours: 17.50 0.90 +5.42%

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $16.60, with a volume of 776.61K. It is up +2.28% in the last 24 hours and up +1.10% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Previous Close:

$16.23

Open:

$16.25

24h Volume:

776.61K

Relative Volume:

2.23

Market Cap:

$1.49B

Revenue:

$14.09M

Net Income/Loss:

$-176.94M

P/E Ratio:

-6.2284

EPS:

-2.6652

Net Cash Flow:

$-141.24M

1W Performance:

+7.30%

1M Performance:

+1.10%

6M Performance:

-29.81%

1Y Performance:

+79.46%

1-Day Range:

$16.25

$16.90

1-Week Range:

$15.19

$16.90

52-Week Range:

$5.6326

$26.35

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

Sep 29, 2024

TD Cowen Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

Sep 29, 2024

Sep 26, 2024

Deerfield Management Company L.P. Series C Has $16.70 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Sep 26, 2024

Sep 25, 2024

Affinity Asset Advisors LLC Boosts Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Sep 25, 2024

Sep 23, 2024

Investment opportunity in NewAmsterdam Pharma stock as anticipation builds for BROADWAY results By Investing.com - Investing.com

Sep 23, 2024

Investment opportunity in NewAmsterdam Pharma stock as anticipation builds for BROADWAY results By Investing.com - Investing.com India

Sep 23, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Overweight" Rating from Piper Sandler - MarketBeat

Sep 23, 2024

Expert Ratings For NewAmsterdam Pharma - Benzinga

Sep 23, 2024

Piper sees ‘attractive buying opportunity’ into NewAmsterdam data - TipRanks

Sep 23, 2024

Sep 21, 2024

'She's A Hardy Filly': Ocean Club Goes All The Way On Front End In Noble Damsel - Paulick Report

Sep 21, 2024

Ocean Club Skims to Narrow Victory in Noble Damsel - BloodHorse.com

Sep 21, 2024

Ocean Club, in quick turnaround, holds off Five Towns, Breath Away to take Noble Damsel - Daily Racing Form

Sep 21, 2024

Trend Tracker for (NAMS) - Stock Traders Daily

Sep 21, 2024

Sep 19, 2024

Next shares rise on upbeat full-year profit outlook By Investing.com - Investing.com Australia

Sep 19, 2024

UK's Next raises forecast to put 1 billion pound profit in sight - Reuters

Sep 19, 2024

Sep 17, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Sep 17, 2024

Sep 06, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Sep 06, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK

Sep 06, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 06, 2024

Sep 05, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat

Sep 05, 2024

Sep 01, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Up 20.7% in August - MarketBeat

Sep 01, 2024

Aug 30, 2024

NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan

Aug 30, 2024

Buying Buzz: NewAmsterdam Pharma Company NV [NAMS] Chief Executive Officer Davidson Michael H. purchases 5,000 shares of the company – Knox Daily - Knox Daily

Aug 30, 2024

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - Yahoo Finance

Aug 30, 2024

Aug 29, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - MarketBeat

Aug 29, 2024

Aug 28, 2024

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Benzinga

Aug 28, 2024

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Yahoo Finance UK

Aug 28, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at Needham & Company LLC - MarketBeat

Aug 28, 2024

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Yahoo Finance

Aug 28, 2024

Aug 27, 2024

NewAmsterdam shares hold Buy rating on strong trial data - Investing.com

Aug 27, 2024